A detailed history of Allspring Global Investments Holdings, LLC transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Allspring Global Investments Holdings, LLC holds 210,531 shares of TARS stock, worth $9.82 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
210,531
Previous 181,066 16.27%
Holding current value
$9.82 Million
Previous $4.92 Million 40.7%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$21.54 - $34.6 $634,676 - $1.02 Million
29,465 Added 16.27%
210,531 $6.92 Million
Q2 2024

Jul 26, 2024

SELL
$25.17 - $38.73 $282,835 - $435,209
-11,237 Reduced 5.84%
181,066 $4.92 Million
Q1 2024

Apr 18, 2024

BUY
$19.61 - $39.22 $95,873 - $191,746
4,889 Added 2.61%
192,303 $6.99 Million
Q4 2023

Jan 25, 2024

SELL
$12.98 - $20.73 $760,082 - $1.21 Million
-58,558 Reduced 23.81%
187,414 $3.8 Million
Q3 2023

Oct 27, 2023

BUY
$14.75 - $24.62 $3.63 Million - $6.06 Million
245,972 New
245,972 $4.37 Million
Q2 2023

Jul 18, 2023

SELL
$11.57 - $19.63 $23,197 - $39,358
-2,005 Reduced 19.04%
8,527 $154,000
Q1 2023

Apr 13, 2023

SELL
$11.92 - $16.27 $1,251 - $1,708
-105 Reduced 0.99%
10,532 $132,000
Q4 2022

Jan 23, 2023

SELL
$14.12 - $18.72 $649 - $861
-46 Reduced 0.43%
10,637 $156 Million
Q3 2022

Oct 26, 2022

SELL
$14.08 - $18.5 $16,572 - $21,774
-1,177 Reduced 9.92%
10,683 $182,000
Q2 2022

Jul 25, 2022

SELL
$11.08 - $19.08 $9,972 - $17,172
-900 Reduced 7.05%
11,860 $173,000
Q1 2022

May 02, 2022

SELL
$14.49 - $24.28 $1,811 - $3,035
-125 Reduced 0.97%
12,760 $214,000
Q4 2021

Jan 28, 2022

BUY
$21.21 - $29.68 $273,290 - $382,426
12,885 New
12,885 $289,000

Others Institutions Holding TARS

About Tarsus Pharmaceuticals, Inc.


  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $1.24B
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.